Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Gastroenterology

Journal Scan / Research · October 15, 2024

Safety and Tolerability of CP101 for the Prevention of Recurrent Clostridioides difficile Infection

Gastroenterology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Gastroenterology
Safety and Tolerability of CP101, a full spectrum, oral microbiome therapeutic for the prevention of recurrent C. difficile infection: A Phase 2 Randomized Controlled Trial
Gastroenterology 2024 Oct 02;[EPub Ahead of Print], JR Allegretti, CR Kelly, T Louie, M Fischer, S Hota, B Misra, NW Van Hise, E Yen, JS Bullock, M Silverman, I Davis, SK McGill, DS Pardi, R Orenstein, A Grinspan, N El-Nachef, P Feuerstadt, TJ Borody, S Khanna S, S Budree, Z Kassam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading